Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of **carboxymethylcellulose** and **omega-3 fatty acids** formulated as an ophthalmic treatment for dry eye disease. Carboxymethylcellulose acts as a lubricant by binding to the ocular surface and mimicking natural tear film mucin, enhancing corneal epithelial cell migration, wound healing, and lubrication. Omega-3 fatty acids, particularly EPA and DHA, modulate inflammation at the ocular surface, influence meibomian gland function to stabilize tear film lipids, and may reduce pro-inflammatory mediators, leading to improved symptoms and signs in dry eye. This combination is aimed at both alleviating dryness through surface protection (carboxymethylcellulose) and modulating ocular surface inflammation and tear stability (omega-3s). Primary indications are **dry eye disease** and ocular surface irritation.[1][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxymethylcellulose + omega-3.